Unicycive Therapeutics, Inc. financial data

Symbol
UNCY on Nasdaq
Location
4300 El Camino Real, Suite 210, Los Altos, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 205 % -0.58%
Quick Ratio 25.1 %
Debt-to-equity 93.1 %
Return On Equity -184 % -242%
Return On Assets -95.3 % -55.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.5M shares -79.3%
Common Stock, Shares, Outstanding 20.9M shares -78.7%
Entity Public Float 18.7M USD -4.22%
Common Stock, Value, Issued 21K USD -78.6%
Weighted Average Number of Shares Outstanding, Basic 18.1M shares +103%
Weighted Average Number of Shares Outstanding, Diluted 18.1M shares +103%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 675K USD
Research and Development Expense 12.2M USD -35.8%
General and Administrative Expense 19.4M USD +89.9%
Operating Income (Loss) -31.6M USD -8.18%
Nonoperating Income (Expense) -1.86M USD -130%
Net Income (Loss) Attributable to Parent -33.4M USD -45.3%
Earnings Per Share, Basic -0.33 USD/shares +28.3%
Earnings Per Share, Diluted 1 USD/shares +28.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 42.7M USD
Inventory, Net 3.11M USD +56.6%
Assets, Current 50.3M USD +33.2%
Property, Plant and Equipment, Net 75K USD +23%
Operating Lease, Right-of-Use Asset 249K USD -67.7%
Assets 50.6M USD +31.2%
Accounts Payable, Current 957K USD +74.6%
Accrued Liabilities, Current 2.76M USD -7.69%
Liabilities, Current 13.1M USD +25.5%
Operating Lease, Liability, Noncurrent 117K USD -74.9%
Liabilities 13.1M USD +22.4%
Retained Earnings (Accumulated Deficit) -113M USD -41.9%
Stockholders' Equity Attributable to Parent 37.5M USD
Liabilities and Equity 50.6M USD +31.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.9M USD -37.9%
Net Cash Provided by (Used in) Financing Activities 2.55M USD -94.4%
Net Cash Provided by (Used in) Investing Activities -16K USD -167%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 20.9M shares -78.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.9M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 42.7M USD +32%
Interest Paid, Excluding Capitalized Interest, Operating Activities 6K USD +20%
Deferred Tax Assets, Valuation Allowance 19.7M USD +76%
Deferred Tax Assets, Gross 19.8M USD +75%
Operating Lease, Liability 265K USD -67.2%
Depreciation 8K USD -11.1%
Payments to Acquire Property, Plant, and Equipment 16K USD +167%
Lessee, Operating Lease, Liability, to be Paid 272K USD -68.8%
Property, Plant and Equipment, Gross 138K USD +50%
Operating Lease, Liability, Current 265K USD -51.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 118K USD -72.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 118K USD -80.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7K USD -89.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 72K USD
Deferred Tax Assets, Operating Loss Carryforwards 11M USD +84.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 1.99M USD +93.3%
Operating Lease, Payments 100K USD 0%
Additional Paid in Capital 151M USD +40.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 169K USD +4.97%
Share-based Payment Arrangement, Expense 2.45M USD +5.48%
Interest Expense 90K USD +66.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares